Mount Sinai’s public menopause service is supported by a regional clinical program and location information. A separate educational interview names progesterone in its hormone-therapy discussion. Reading those records together requires care: a hormone mentioned in education is not automatically an identified product offered by the service.
This assessment was reviewed September 29, 2026. It distinguishes the dated interview from current service descriptions and from product-specific labeling. No Mount Sinai prescription or package has been examined, and no micronized formulation, pharmacy or outcome is attributed to the institution on the strength of the hormone name alone.
Read this article by section
The educational interview has a date and a limited purpose
Mount Sinai’s menopause interview is dated May 26, 2021. It discusses hormone therapy and names progesterone, but it does not identify a particular finished preparation. Its publication date matters when the reader is comparing that discussion with a current product label.
This review does not republish its broad treatment-benefit statements as a contemporary prescribing rule. It uses the interview only to examine the specificity of the medicine term. The Hopkins review similarly separates institutional education from the service’s actual offer. An institution’s authorship does not make every educational sentence a current formulary entry, an individual recommendation or evidence that a specific capsule can be obtained there.
The clinical service is confirmed by a different record
The menopause service page describes care for concerns including abnormal bleeding, hot flashes and sexual dysfunction. That is the evidence for relevant clinical care. The older interview is not being used as the sole reason to include Mount Sinai among providers.
This distinction prevents two errors: mistaking a publisher of education for a care service, and assuming that a real service supplies every preparation familiar from that subject. Mount Sinai’s record supports the first question but leaves the exact micronized product unanswered. A concern on its care menu also does not assign that concern to progesterone, establish a diagnosis or demonstrate that every patient will receive hormone treatment.
Progesterone and progestin should not be silently exchanged
The FDA explanation of menopausal hormone therapy distinguishes progesterone and progestin within the broader progestogen category. A general statement about one category should not erase the identity of the active ingredient actually being discussed. The interview’s word progesterone is therefore worth preserving accurately, even though it leaves the product unspecified.
Our progesterone and progestin guide explains why the vocabulary matters. This review does not borrow an outcome or warning from an unnamed member of the category and call it a result for Mount Sinai’s future prescription. Nor does identifying the hormone establish that an individual formulation is approved, compounded, micronized or suitable for a particular person.
Micronized cannot be supplied by association
The interview does not provide an exact micronized capsule record. That missing information should not be filled in because the subject is menopause or because a commonly discussed oral product exists. The name of an active substance and the description of a formulation are separate information.
The micronized terminology article provides background without authenticating any Mount Sinai medicine. Readers comparing Northwestern’s review will encounter another property—off-label use—that also cannot be inferred from a hormone name. These distinctions narrow what can responsibly be claimed. They are not an instruction to select a preparation or evidence that one formulation necessarily performs better than another.
A label would need to correspond to the proposed item
The exact Prometrium record contains formulation and inactive-ingredient information for that named product. It is a useful example of the specificity absent from the Mount Sinai service description. It is not a substitute label for an unidentified future prescription.
The route guide likewise cannot turn the product example into a Mount Sinai offer. A capsule’s ingredient list should not be assigned to a cream, another manufacturer’s item or a compounded preparation. No such package comparison was performed here. The eventual product and the evidence relevant to its proposed use would need to be identified by the prescribing and dispensing professionals, not guessed from the institution’s educational vocabulary.
New York locations do not define a nationwide supply channel
Mount Sinai’s menopause location directory identifies New York City practices. Those entries support a regional service footprint. They do not confirm unrestricted remote care, a shared pharmacy arrangement or shipment of a selected progesterone product throughout the country.
The reviewed pages also do not establish an all-inclusive treatment price. A prospective patient would need the relevant office’s appointment and billing information, with any eventual medicine cost distinguished from the visit. This assessment has not verified insurance benefits, availability or a purchase. Regional clinical access is meaningful information on its own; it should not be enlarged into a national product offer merely because the educational material is publicly accessible.
Keep the dated explanation and the current proposal separate
The current service description supports a straightforward conclusion: Mount Sinai offers menopause care, while the public records reviewed here leave the exact micronized medicine unidentified. The older educational interview helps examine a term, not establish the present details of an individual prescription.
That boundary should survive comparison with more detailed commercial listings. A longer list of product specifications elsewhere cannot be imported into Mount Sinai’s record. Useful clarification would identify what preparation is actually proposed and why its particular evidence applies. Until then, this review reports the verified service and the formulation gap without a patient testimonial, clinical endorsement or invented account of how the institution dispenses progesterone.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Mount Sinai — What Can I Do About My Menopause Symptoms?Institutional educational interview dated May 26, 2021; used only for the documented progesterone term and unspecified formulation. Broad benefit and age statements are not adopted as current product evidence. · Checked 2026-09-29
- Mount Sinai — Menopause Care and TreatmentsOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29
- FDA — Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsFederal primary therapy-category explanation. Active ingredients remain distinct; requested labeling changes do not establish removal of every warning or identify a clinic product. · Checked 2026-09-29
- DailyMed — PROMETRIUM progesterone capsule, Acertis Pharmaceuticals LLCExact identified oral product labeling, updated July 23, 2026; text only, no package-image inspection. Ingredient, formulation and WHI study details are not assigned to a health-system prescription. · Checked 2026-09-29
- Mount Sinai — Menopause Treatment LocationsOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29